Triple-Negative Breast Cancer

11 · 20 / page

Ask MedXY AI

Latest news

Tag

newsantibody-drug conjugatespembrolizumab

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

By MedXY|Jan 25, 2026

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients wi

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

Hematology-Oncologyadjuvant therapyCarboplatin

Triple-Negative Breast Cancer

Latest news

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

The Dark Side of Olive Oil: High-Oil Diets Promote Lung Metastasis in Triple-Negative Breast Cancer

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer